Discover what’s new in the updated Good Clinical Practice guideline: ICH E6 (R3)

The International Council for Harmonisation (ICH) published the third revision (R3) of the ICH E6 guideline in late 2023. This global standard offers ethical and scientific guidance for conducting clinical trials involving human subjects, ensuring the rights, safety, and well-being of participants. GCP principles were developed in response to unethical practices in early human research, with foundational references including the Declaration of Helsinki and the Nuremberg Code.

The core objective of GCP is to ensure that clinical trials are conducted in accordance with ethical principles, such as those outlined in the Declaration of Helsinki, and to guarantee that the data generated are credible and scientifically robust. GCP guidelines also aim to ensure the validity of data for regulatory decisions regarding the safety and efficacy of investigational products, thereby reinforcing public trust in clinical research.

The New GCP: ICH E6 (R3)

ICH E6 (R3) introduces a more flexible, risk-based framework for quality management in clinical trials. This approach enables trials to be more adaptive and tailored to the specific characteristics of each study, while maintaining the highest standards for participant safety and data integrity.

1. Innovation in design and technology:
   The revised guideline emphasizes the integration of technological and methodological advances in trial design. This includes the use of digital health technologies (DHTs) and real-world data (RWD), promoting greater efficiency and adaptability in study execution.
2. Quality by Design (QbD):
   ICH E6 (R3) highlights the importance of embedding quality into the design and operational planning of clinical trials. A risk-proportionate approach is encouraged, focusing on elements that are critical to participant protection and data reliability.
3. Transparency and trial registration:
   The new guideline strengthens expectations for transparency through mandatory trial registration in publicly accessible databases and the objective, non-promotional dissemination of study results.

Key Changes from ICH E6 (R2)

The transition from E6 (R2) to E6 (R3) reflects both the evolution of trial methodologies and lessons learned from past implementations. Major updates include:

1. Greater flexibility:
   In contrast to the prescriptive, “one-size-fits-all” approach of E6 (R2), the new revision supports a flexible application of GCP principles that can be adapted based on the nature and context of each trial.
2. Clearer roles and responsibilities:
   E6 (R3) requires that roles and responsibilities in clinical trials be clearly defined, assigned, and documented—promoting accountability and operational clarity.
3. Improved clarity and usability:
   The guideline is now more accessible and easier to interpret for sponsors, investigators, and other stakeholders, thanks to clearer language and more actionable directives.
4. Enhanced Quality by Design Approach:
   The QbD methodology in E6 (R3) guides stakeholders to identify the factors—such as data points or processes—critical to trial quality, and to design mitigation strategies proportionate to the associated risks.
5. Expanded Informed Consent requirements:
   Additional detail has been added regarding the informed consent process, emphasizing the participant’s right to fully understand the trial’s risks and benefits. The use of digital tools to facilitate informed consent in urgent or emergency settings is also addressed.
6. Data governance:
   A new section on data governance outlines expectations for managing large datasets and the application of advanced technologies to ensure data security and integrity.

Implications for Clinical Trial sponsors

The implementation of ICH E6 (R3) has far-reaching implications for sponsors, including pharmaceutical and biotech companies, CROs, and research institutions. By embracing a risk-based, quality-by-design approach, organizations can enhance the efficiency and effectiveness of clinical trials, reduce operational burdens, and improve resource allocation. Increased transparency and better trial registration practices are also expected to boost public confidence and support broader collaboration across the research ecosystem.

There is widespread consensus that ICH E6 (R3) marks a meaningful evolution in GCP regulation—one that aligns with contemporary research practices and facilitates higher standards of data quality and patient protection. Industry stakeholders must proactively prepare to implement these changes and seize the opportunity to modernize their clinical trial processes.

By Kenia Flores, Head of the Quality Department at Sermes CRO

• By Sermes CRO
• 08/05/2025
• GCP, ICH E6 (R3)